Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of “Hold” by Brokerages

Theravance Biopharma, Inc. (NASDAQ:TBPH) has received an average recommendation of “Hold” from the five ratings firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $13.75.

A number of equities analysts have commented on the company. Leerink Partnrs downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Leerink Partners downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th. TD Cowen decreased their target price on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a research note on Monday, September 16th. Finally, StockNews.com downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th.

Theravance Biopharma Stock Performance

NASDAQ:TBPH opened at $8.02 on Wednesday. The company has a market capitalization of $390.04 million, a price-to-earnings ratio of -9.33 and a beta of 0.24. Theravance Biopharma has a one year low of $7.44 and a one year high of $11.71. The stock has a 50-day simple moving average of $8.62 and a 200 day simple moving average of $8.85.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). The firm had revenue of $14.26 million during the quarter, compared to analyst estimates of $15.81 million. Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. During the same quarter last year, the business posted ($0.28) earnings per share. On average, equities research analysts forecast that Theravance Biopharma will post -1.04 EPS for the current fiscal year.

Insider Activity

In related news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now owns 335,965 shares of the company’s stock, valued at $3,023,685. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now owns 335,965 shares of the company’s stock, valued at $3,023,685. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Eli Samaha bought 999,800 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were purchased at an average cost of $7.80 per share, for a total transaction of $7,798,440.00. Following the acquisition, the insider now owns 9,511,150 shares of the company’s stock, valued at $74,186,970. The disclosure for this purchase can be found here. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. increased its holdings in shares of Theravance Biopharma by 41.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company’s stock valued at $5,005,000 after buying an additional 163,951 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Theravance Biopharma by 38.4% in the second quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock valued at $2,800,000 after buying an additional 91,679 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Theravance Biopharma by 83.6% in the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock valued at $2,523,000 after buying an additional 135,426 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Theravance Biopharma by 68.0% in the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock valued at $3,227,000 after buying an additional 116,164 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of Theravance Biopharma by 6.3% in the first quarter. SG Americas Securities LLC now owns 209,566 shares of the biopharmaceutical company’s stock valued at $1,880,000 after buying an additional 12,460 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.